Search
Now showing items 1-2 of 2
In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype
(The British Pharmacological Society, 2010)
AIMS
This study aimed to test whether a pharmacokinetic simulation model
could extrapolate nonclinical drug data to predict human efavirenz
exposure after single and continuous dosing as well as the effects of
concomitant ...
HIV/AIDS patients display lower relative bioavailability of Efavirenz than healthy subjects
(Adis Data Information BV., 2011)
Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and ...